75 search results for: type 2 inflammation

expert video

Neuroimmune Axis Dysregulation and Type 2 Inflammation: Shared Roles in AD, PN, and CSU

9 min

Dermatology

Exploration of the shared type 2 inflammation and neuroimmune axis dysfunction in AD, PN, and CSU leading to itch.

<b>Type</b> <b>2</b> <b>Inflammation</b> in AD Manifestations in Skin and Body

expert video

Type 2 Inflammation in AD Manifestations in Skin and Body

6 min

Dermatology

Dr. Ramien discusses the role of type 2 inflammation in the pathophysiology of atopic dermatitis, and highlights the association of atopic dermatitis with systemic diseases and comorbidities.

The Role of <b>Type</b> <b>2</b> <b>Inflammation</b> in Atopic Dermatitis

expert video

The Role of Type 2 Inflammation in Atopic Dermatitis

1 min

Dermatology

The impact of type 2 inflammation and barrier dysfunction in the pathogenesis of chronic disease in atopic dermatitis.

Clinical Presentations in AD, PN, and CSU: Role of <b>Type</b> <b>2</b> <b>Inflammation</b>

expert video

Clinical Presentations in AD, PN, and CSU: Role of Type 2 Inflammation

20 min

Dermatology

Review the role of type 2 inflammation in the skin manifestations and itch in these chronic skin conditions.

The Role of <b>Type</b> <b>2</b> <b>Inflammation</b> in Skin Barrier Dysfunction in Atopic Dermatitis

expert video

The Role of Type 2 Inflammation in Skin Barrier Dysfunction in Atopic Dermatitis

2 min

Dermatology

Dr. Robert Bissonnette highlights the role of type 2 inflammation in skin barrier dysfunction in atopic dermatitis.

<b>Type</b> <b>2</b> <b>Inflammation</b> and Neuroimmune Axis Dysregulation in AD, PN, and CSU

expert video

Type 2 Inflammation and Neuroimmune Axis Dysregulation in AD, PN, and CSU

3 min

Dermatology

Examination of the unique ways type 2 inflammation contributes to itch in AD, PN, and CSU.

Overview of <b>Type</b> <b>2</b> <b>Inflammation</b> in the Presentations of AD, PN, and CSU

expert video

Overview of Type 2 Inflammation in the Presentations of AD, PN, and CSU

2 min

Dermatology

Dr. Eric Simpson summarizes the role of type 2 inflammation in the clinical manifestations of AD, PN, and CSU.

The Role of <b>Type</b> <b>2</b> <b>Inflammation</b> in Moderate-to-Severe AD

expert video

The Role of Type 2 Inflammation in Moderate-to-Severe AD

4 min

Dermatology

In this expert interview video focusing on topics from the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands, Dr. Stephan Weidinger discusses how type 2 inflammation contributes to the systemic inflammation seen in patients with moderate-to-severe AD.

Diving Below the Surface of AD: The Role of <b>Type</b> <b>2</b> <b>Inflammation</b>

expert video

Diving Below the Surface of AD: The Role of Type 2 Inflammation

10 min

Dermatology

This video from the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands, features Dr. Stephan Weidinger discussing how local type 2 inflammation at the skin tissue level contributes to epidermal barrier dysfunction, dysbiosis, and neuroimmune dysfunction, leading to the clinical signs and symptoms of AD. Dr. Weidinger also reviews how systemic inflammation affects organ systems beyond the skin and can manifest as atopic and non-atopic comorbidities.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: South AfricaChange country/region